F
Frédéric Bibeau
Researcher at University of Caen Lower Normandy
Publications - 206
Citations - 11935
Frédéric Bibeau is an academic researcher from University of Caen Lower Normandy. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 49, co-authored 186 publications receiving 10219 citations. Previous affiliations of Frédéric Bibeau include ICM Partners & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Astrid Lièvre,Jean-Baptiste Bachet,Valérie Boige,Anne Cayre,Delphine Le Corre,Emmanuel Buc,Marc Ychou,Olivier Bouché,Bruno Landi,Christophe Louvet,Thierry André,Frédéric Bibeau,Marie-Danièle Diebold,Philippe Rougier,Michel Ducreux,Gorana Tomasic,Jean-François Emile,Frédérique Penault-Llorca,Pierre Laurent-Puig +18 more
TL;DR: These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetUXimab.
Journal ArticleDOI
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig,Anne Cayre,Gilles Manceau,Emmanuel Buc,Jean-Baptiste Bachet,Thierry Lecomte,Philippe Rougier,Astrid Lièvre,Bruno Landi,Valérie Boige,Michel Ducreux,Marc Ychou,Frédéric Bibeau,Olivier Bouché,Julia Reid,Steven Stone,Frédérique Penault-Llorca +16 more
TL;DR: Braf status, EGFR amplification, and cytoplasmic expression of PTEN were associated with outcome measures in KRAS wild-type patients treated with a cetuximab-based regimen, and subsequent studies in clinical trial cohorts will be required to confirm the clinical utility of these markers.
Journal ArticleDOI
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Pierre Farmer,Pierre Farmer,Pierre Farmer,Hervé Bonnefoi,Pascale Anderle,David Cameron,David Cameron,Pratyakasha Wirapati,Véronique Becette,Sylvie André,Martine Piccart,Mario Campone,Etienne Brain,Gaëtan MacGrogan,Thierry Petit,Jacek Jassem,Frédéric Bibeau,Emmanuel Blot,Jan Bogaerts,Michel Aguet,Jonas Bergh,Richard Iggo,Richard Iggo,Mauro Delorenzi,Mauro Delorenzi +24 more
TL;DR: It is reported that increased stromal gene expression predicts resistance to preoperative chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in subjects in the EORTC 10994/BIG 00-01 trial and suggests that antistromal agents may offer new ways to overcome resistance to chemotherapy.
Journal ArticleDOI
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Alain R. Thierry,Florent Mouliere,Safia El Messaoudi,Caroline Mollevi,Evelyne Lopez-Crapez,Fanny Rolet,Brigitte Gillet,Céline Gongora,Pierre Déchelotte,Bruno Robert,Maguy Del Rio,Pierre-Jean Lamy,Frédéric Bibeau,Michelle Nouaille,Virginie Loriot,Anne Sophie Jarrousse,Franck Molina,Muriel Mathonnet,Denis Pezet,Marc Ychou +19 more
TL;DR: This study shows that liquid biopsy through cfDNA analysis could advantageously replace tumor-section analysis and expand the scope of personalized medicine for patients with cancer.
Journal ArticleDOI
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
Claudio Luchini,Frédéric Bibeau,Marjolijn J. L. Ligtenberg,Naveena Singh,Alessia Nottegar,Tjalling Bosse,Rowan Miller,Nadeem Riaz,J.-Y. Douillard,Fabrice Andre,Aldo Scarpa +10 more
TL;DR: This ESMO initiative is a response to the urgent questions raised by the growing success of immunotherapy and provides also important insights on the relationships between MSI, TMB and PD-1/PD-L1 expression.